Abstract: Provided are androstane and dihydrotestosterone compounds functionalized with carbocyclic groups or heterocyclic groups that may be saturated or unsaturated. The compounds may be used in methods of inhibiting cell growth of malignant cells and/or hyperplastic cells and/or treating individuals having diseases associated with malignant cell growth (e.g., cancer, such as, for example, prostate cancer) and/or hyperplastic cell growth and/or molecular imaging of malignant cells and/or hyperplastic cells and/or inducing degradation of a target protein. Also provided are compositions.

Abstract: A method of inhibiting activity or expression of one or more 3?-oxidoreductase enzymes that share a common catalytic site and convert androstanediol to DHT. The method comprises introducing one or more agents into cells that comprise the one or more 3?-oxidoreductase enzymes, wherein said one or more agents: i) inhibit function of one or more of said enzymes; ii) inhibit translation of mRNA encoding said enzymes; iii) disrupt or delete genes encoding said enzymes; or a combination thereof.

Abstract: The present disclosure may be embodied as an incontinence device for a catheterized individual. The device includes an absorbent pad configured to be worn by the individual. The absorbent pad having a slit partially separating the pad into two portions. A fastener may be provided for selectively attaching the two portions to each other. In this way, a catheter may be disposed through the slit of the device and the two portions may be attached to each other using the fastener to surround a circumference of the catheter. The fastener may be reusable. In some embodiments, the device includes more than one fastener. The fastener may be one or more of an adhesive, a hook-and-loop fastener, a snap fastener, or combinations thereof.

Abstract: Methods and compositions which are directed against catalytic site common to multiple 3 alpha-oxidoreductases. The compositions can be used for the treatment of prostate cancer.

Abstract: The invention provides an isolated, novel steroid 5?-reductase enzyme termed SRD5AIII. The protein has an estimated molecular weight of 37 kDa and is capable of converting testosterone to dihydrotestosterone at a pH of about 7.0. Also provided is a method for identifying inhibitors of SRD5AIII by contacting SRD5AIII with a test compound and measuring the activity of the enzyme. A reduced activity relative to a control indicates that the test compound is an inhibitor of SRD5AIII. A method is also provided for detecting androgen stimulated prostate cancer or recurrent prostate cancer in an individual. The method comprises obtaining a prostate biopsy from an individual and determining the level of expression of SRD5AIII gene or protein relative to a normal control. An increased expression of SRD5AIII relative to the control is indicative of androgen stimulated prostate cancer or recurrent prostate cancer.

Abstract: The invention provides an isolated, novel steroid 5?-reductase enzyme termed SRD5AIII. The protein has an estimated molecular weight of 37 kDa and is capable of converting testosterone to dihydrotestosterone at a pH of about 7.0. Also provided is a method for identifying inhibitors of SRD5AIII by contacting SRD5AIII with a test compound and measuring the activity of the enzyme. A reduced activity relative to a control indicates that the test compound is an inhibitor of SRD5AIII. A method is also provided for detecting androgen stimulated prostate cancer or recurrent prostate cancer in an individual. The method comprises obtaining a prostate biopsy from an individual and determining the level of expression of SRD5AIII gene or protein relative to a normal control. An increased expression of SRD5AIII relative to the control is indicative of androgen stimulated prostate cancer or recurrent prostate cancer.

Abstract: Provided is a method for determining the presence or amount of 5-?-dihydro-3-keto steroids (ADKSs) comprising the steps of preparing a sample for chromatographic separation, subjecting the sample to chromatographic separation, subjecting the chromatographically separated sample to atmospheric pressure photoionization (APPI), and detecting the amount of alkylated parent ions using mass spectrometry or methylated daughter ions by mass spectrometry after collisionally induced dissociation of the alkylated parent ions. Tandem mass spectrometry of ADKSs with a 6-member A ring and a 3-keto group using APPI and methanol as the alkoxy donor will produce methylated daughter ions with a mass/charge ratio of 85.0. Quantitation of this alkylated daughter ion provides a method to detect very low levels of ADKSs such as DHT. This method can also be used for the simultaneous detection of ADKSs and non-ADKSs.